Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DEXCOM INCDXCM · Entity 3114 | Director · Executive Chair | August 20, 2026 | August 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DEXCOM INC
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 302,214 |
Last balance in matching sequence
After 2026-08-20 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-08-20 · Sale · Disposed 19,308 · Balance 309,662 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 2 · 2026-08-20 · Sale · Disposed 7,351 · Balance 302,311 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. Row 3 · 2026-08-20 · Sale · Disposed 97 · Balance 302,214 F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan. F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 18, 2026, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5- 1 Plan.
F2: This transaction was executed in multiple trades at prices ranging from $89.275 to $90.25. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3: Included in this number are 106,972 unvested restricted stock units, 32,749 of which were granted on March 8, 2026 and shall vest through March 8, 2027, 56,993 of which were granted on March 8, 2025 and shall vest through March 8, 2028, and 17,230 of which were granted on March 8, 2024 and shall vest through March 8, 2027.
F4: This transaction was executed in multiple trades at prices ranging from $90.32 to $91.19. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 09, 2018 Filed May 10, 2018 23:54 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 17,245 | $84.37 | $1,454,991.69 |
DisclosureSEC source: 0001093557-18-000089 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,390 F1 · shares: The reporting person exercised options that were granted in 2008 and scheduled to expire on May 19, 2018. He sold shares to pay the exercise price and associated taxes on the options, and retained the net number of shares. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.29 to $84.67. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| May 09, 2018 Filed May 10, 2018 23:54 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 31,464 | $7.63 | $240,070.32 |
DisclosureSEC source: 0001093557-18-000089 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366,635 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:01 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 7,297 | $60.73 | $443,151.19 |
DisclosureSEC source: 0001093557-18-000053 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,171 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:01 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 5,283 | $60.73 | $320,839.76 |
DisclosureSEC source: 0001093557-18-000053 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 342,468 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 12, 2018 Filed Mar 15, 2018 01:01 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 13,620 | $60.73 | $827,150.77 |
DisclosureSEC source: 0001093557-18-000053 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,751 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 01:33 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 80,545 | $0.00 | $80.55 |
DisclosureSEC source: 0001093557-18-000037 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,371 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 164,731 unvested restricted stock units, 80,545 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 54,186 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 30,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019. Read SEC document |
| December 12, 2017 Filed Dec 13, 2017 22:07 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,000 | $58.85 | $353,092.20 |
DisclosureSEC source: 0001093557-17-000241 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,826 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016, as amended effective August 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $58.01 to $59.43. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 141,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 45,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| November 20, 2017 Filed Nov 21, 2017 22:09 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 12,000 | $55.00 | $660,000.00 |
DisclosureSEC source: 0001093557-17-000229 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,826 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016, as amended effective August 17, 2017. F2 · balance_after: Included in this number are 141,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 45,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 22:13 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,000 | $69.34 | $416,044.20 |
DisclosureSEC source: 0001093557-17-000201 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,826 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016, as amended effective August 17, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.02 to $69.57. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 141,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 45,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:38 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 7,927 | $71.81 | $569,264.82 |
DisclosureSEC source: 0001093557-17-000199 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,826 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 141,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 45,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 22:38 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 7,927 | $71.81 | $569,264.82 |
DisclosureSEC source: 0001093557-17-000199 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,753 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 141,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 45,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 21:52 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,000 | $69.77 | $418,636.80 |
DisclosureSEC source: 0001093557-17-000175 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $69.63 to $70.03. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| July 12, 2017 Filed Jul 12, 2017 21:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,000 | $71.86 | $431,174.40 |
DisclosureSEC source: 0001093557-17-000161 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.31 to $72.00. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| June 12, 2017 Filed Jun 13, 2017 21:26 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 6,000 | $69.07 | $414,411.00 |
DisclosureSEC source: 0001093557-17-000152 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $68.49 to $69.60. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| May 17, 2017 Filed May 18, 2017 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,649 | $68.40 Strike: $8.79 | $249,599.99 |
DisclosureSEC source: 0001093557-17-000125 · edgardoc.xml · derivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,649 shares Expires 2017-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2017 Filed May 18, 2017 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 5,000 | $68.39 | $341,925.00 |
DisclosureSEC source: 0001093557-17-000125 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $67.86 to $68.89. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| May 17, 2017 Filed May 18, 2017 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,649 | $68.40 | $249,599.99 |
DisclosureSEC source: 0001093557-17-000125 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $67.86 to $69.50. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| May 17, 2017 Filed May 18, 2017 21:46 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 3,649 | $8.79 | $32,074.71 |
DisclosureSEC source: 0001093557-17-000125 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 21:20 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $75.63 Strike: $8.79 | $756,317.00 |
DisclosureSEC source: 0001093557-17-000101 · edgardoc.xml · derivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,649 Underlying: Common Stock · 10,000 shares Expires 2017-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 21:20 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 10,000 | $75.63 | $756,317.00 |
DisclosureSEC source: 0001093557-17-000101 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $75.20 to $76.23. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 21:20 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 10,000 | $8.79 | $87,900.00 |
DisclosureSEC source: 0001093557-17-000101 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 22:03 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $77.82 Strike: $8.79 | $778,158.00 |
DisclosureSEC source: 0001093557-17-000089 · edgardoc.xml · derivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,649 Underlying: Common Stock · 10,000 shares Expires 2017-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 22:03 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 10,000 | $77.82 | $778,158.00 |
DisclosureSEC source: 0001093557-17-000089 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,680 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $77.16 to $78.75. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 17, 2017 Filed Mar 21, 2017 22:03 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 10,000 | $8.79 | $87,900.00 |
DisclosureSEC source: 0001093557-17-000089 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 11, 2017 01:48 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 7,927 | $77.55 | $614,743.61 |
DisclosureSEC source: 0001093557-17-000064 · edgardoc.xml · nonDerivative · entry 4 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,680 F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:48 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 15,853 | $77.55 | $1,229,409.66 |
DisclosureSEC source: 0001093557-17-000064 · edgardoc.xml · nonDerivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,607 F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:48 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 13,211 | $77.55 | $1,024,520.98 |
DisclosureSEC source: 0001093557-17-000064 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,460 F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 01:48 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 81,280 | $0.00 | $81.28 |
DisclosureSEC source: 0001093557-17-000064 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,671 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock. F2 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:14 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $81.62 Strike: $8.79 | $816,177.00 |
DisclosureSEC source: 0001093557-17-000033 · edgardoc.xml · derivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,649 Underlying: Common Stock · 10,000 shares Expires 2017-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:14 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 10,000 | $81.62 | $816,177.00 |
DisclosureSEC source: 0001093557-17-000033 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,391 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.64 to $82.10. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 160,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 45,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 25,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 23:14 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 10,000 | $8.79 | $87,900.00 |
DisclosureSEC source: 0001093557-17-000033 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 01:33 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $85.94 Strike: $8.79 | $859,362.00 |
DisclosureSEC source: 0001093557-17-000015 · edgardoc.xml · derivative · entry 3 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,649 Underlying: Common Stock · 10,000 shares Expires 2017-11-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 01:33 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 10,000 | $85.94 | $859,362.00 |
DisclosureSEC source: 0001093557-17-000015 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,391 F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $85.00 to $86.53. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 160,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 45,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 25,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| January 17, 2017 Filed Jan 20, 2017 01:33 UTC | DEXCOM INC DXCM · Entity 3114 | Exercise / conversionCommon Stock | 10,000 | $8.79 | $87,900.00 |
DisclosureSEC source: 0001093557-17-000015 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,391 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2016 Filed Dec 17, 2016 00:20 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-16-000761 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,391 F1 · shares: This transaction represents a gift of securities made by the reporting person. This is not a market transaction, thus no price has been reported. Transferor retains no beneficial or voting interest in the transferred shares. F2 · balance_after: Included in this number are 160,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 45,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 25,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 00:25 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,000 | $81.87 | $573,100.50 |
DisclosureSEC source: 0001093557-16-000725 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,891 F1 · shares: On December 14, 2015, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.07 to $82.39. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 160,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 45,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 25,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 21:35 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7,000 | $91.79 | $642,526.50 |
DisclosureSEC source: 0001093557-16-000705 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,891 F1 · shares: On December 14, 2015, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $90.64 to $92.33. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 160,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 45,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 25,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:30 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 13,335 | $93.72 | $1,249,790.87 |
DisclosureSEC source: 0001093557-16-000690 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,891 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 160,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 45,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 25,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:30 UTC | DEXCOM INC DXCM · Entity 3114 | Disposition to issuerCommon Stock | 8,001 | $93.72 | $749,874.52 |
DisclosureSEC source: 0001093557-16-000690 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,226 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 160,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 45,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 25,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.